Drug Delivery & Formulation Summit 2019
This presentation, delivered by Nikki Whitfield VP, CDMO Services, at the Drug Delivery & Formulation Summit 2019 (DDF) in Berlin, explains how to quickly develop first-in-human (FIH) dosage forms and bridge to drug products for proof-of-concept (POC).
Watch the presentation and learn about:
- Choosing the appropriate dosage form for first-in-human/Phase I trials
- Compounding or GMP manufacturing – how to balance cost, time and dose flexibility
- Challenges with poorly soluble molecules in early development – what technologies can we deploy?
- Bridging to robust and scalable Phase II drug products – how to avoid losing time in development?
- Highly flexible and adaptive clinical manufacturing strategies for patient trials – how can real-time manufacturing be used?
About Nikki Whitfield
Nikki possesses 25 years’ experience in the pharmaceutical industry and has previously held technical leadership positions in Quadrant Healthcare, Quadrant Drug Delivery and Elan where she was responsible for the development, transfer and scale up of both early phase and late phase spray-dried inhaled and topical products intended for both European and U.S. markets. In her previous position as a Project Director at Vectura, she led the early phase product development for two inhaled, orphan indication products and the late stage development for a novel sterile topical product. Nikki’s responsibilities at Quotient Sciences involve building the global formulation and manufacturing services business.
First-in-Human to Proof-of-Concept
Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.
First-in-Human to Proof-Of-Concept: Addressing Development Challenges and Accelerating Timelines
Increasing pressure on R&D budgets means the design, speed and precision of early phase clinical programs is critical for success.
Formulation selection and development for ME-401 during a first-in-human study in healthy volunteers - AAPS 2016
Formulation selection and development for ME-401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ during a first-in-human study in healthy volunteers.
Formulation Development - Spray Drying
We use a broad range of formulation approaches to address complex solubility and bioavailability challenges, ensuring technology selection is driven by molecule need.